ICON Launches FIRECREST
ICON plc has announced the release of two new digital solutions supporting clinical research sites and sponsors. The FIRECREST suite of digital clinical solutions are now integrated with the ICON Safety Reporting solution to enable electronic acknowledgement of safety letters by principal investigators, with compliance tracking and dashboard reporting.
FIRECREST Safety Letters aims to supports sites to manage safety letters and increase transparency for sponsors.FIRECREST Site Question Management provides medical query routing according to region and role. A record of the interactions and metadata are held centrally in the site portal for oversight purposes and an exportable excel document can be filed in the eTMF.
For more information, click here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
